(Q39642410)

13 September 2017

1 reference

title

Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis (English)

1 reference

primary biliary cholangitis

13 September 2017

0 references

0 references

author name string

Wiesner RH

1

1 reference

13 September 2017

Grambsch PM

2

1 reference

13 September 2017

Lindor KD

3

1 reference

13 September 2017

Ludwig J

4

1 reference

13 September 2017

Dickson ER

5

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 May 1988

1 reference

13 September 2017

1 reference

13 September 2017

volume

8

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

668-676

1 reference

The medical review article: state of the science

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

Long-Term Therapy of Wilson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

NIH conference: Primary biliary cirrhosis: a model autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Complement components and activation in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Circulating immune complexes and complement activation in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Suppressor cell activity in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Autoreactivity against biliary tract antigens in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Circulating activated B cells in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Rheumatic disorders in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Ultrastructural lesions of bile ducts in primary biliary cirrhosis. A comparison with the lesions observed in graft versus host disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

D-penicillamine treatment improves survival in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Sample-size formula for the proportional-hazards regression model

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Introduction to sample size determination and power analysis for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

PENICILLAMINE THERAPY FOR HEPATOLENTICULAR DEGENERATION

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Collagen Defect induced by Penicillamine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Trial of penicillamine in advanced primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

A prospective trial of D-penicillamine in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Inhibition of Collagen Secretion from Bone and Cultured Fibroblasts by Microtubular Disruptive Drugs

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Colchicine-Induced Modulation of Collagenase in Human Skin Fibroblast Cultures. I. Stimulation of Enzyme Synthesis in Normal Cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

The action of colchicine in acute gouty arthritis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

A prospective trial of colchicine for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Randomized trial of chlorambucil for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840080339

7 January 2021

Identifiers

DOI

10.1002/HEP.1840080339

1 reference

13 September 2017

1 reference